Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moss GenomicsFRA:F73 Equity-to-Asset is 0.87 as of Mar. 2026, which is 38% above its 10-year median of 0.63. Among 684 Healthcare Providers & Services companies, Moss Genomics ranks better than 93.27% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Moss Genomics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €0.71 Mil. Moss Genomics's Total Assets for the quarter that ended in Mar. 2026 was €0.82 Mil.
The historical rank and industry rank for Moss Genomics's Equity-to-Asset or its related term are showing as below:
FRA:F73'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.09 Med: 0.63 Max: 0.94
Current: 0.87
During the past 4 years, the highest Equity to Asset Ratio of Moss Genomics was 0.94. The lowest was -1.09. And the median was 0.63.
FRA:F73's Equity-to-Asset is ranked better than 93.27% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 0.485
vs FRA:F73: 0.87
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Moss Genomics Equity-to-Asset Related Terms
Moss Genomics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Moss Genomics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F73 vs VEEV, BTSG, TEM: Equity-to-Asset Comparison
For the Health Information Services subindustry, Moss Genomics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moss Genomics Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Moss Genomics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Moss Genomics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Moss Genomics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moss Genomics (FRA:F73) has a Equity-to-Asset of 0.87 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Moss Genomics and its competitors. This is 38% above median its historical median of 0.63. According to the industry distribution chart, Moss Genomics ranks #46 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 6.7%.
Is Moss Genomics' Equity-to-Asset too high?
Moss Genomics' current Equity-to-Asset of 0.87 is 38% above median its 10-year median of 0.63. The Healthcare Providers & Services industry median Equity-to-Asset is 0.49. Moss Genomics' value of 0.87 is 79.4% above this industry median. Based on the distribution chart, Moss Genomics ranks #46 out of 684 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Moss Genomics' Equity-to-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Moss Genomics ranks #46 out of 684 companies for Equity-to-Asset. This places Moss Genomics in the top 7% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.49. Moss Genomics' value of 0.87 is 79.4% above this benchmark. While the company's 10-year median is 0.63 vs. the industry median of 0.49, Moss Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.49, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moss Genomics's current Equity-to-Asset of 0.87 is 79.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Moss Genomics and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moss Genomics's current Equity-to-Asset is 0.87, which is 38% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moss Genomics stock overvalued right now?
Moss Genomics (FRA:F73) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is 38% above median its 10-year median of 0.63 and 79.4% above the Healthcare Providers & Services industry median of 0.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Moss Genomics (FRA:F73), the current Equity-to-Asset is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moss Genomics Inc is an emerging consumer genomics company that provides personalized health, anti-aging, and wellness solutions based on genomic, microbiome, and epigenome data. It aims to eliminate barriers in healthcare by offering accessible, affordable at-home testing along with easy-to-understand actionable results.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F73 has been successfully added to your 
